Vertex, Inc. (NASDAQ:VERX) announced on Tuesday that president and CEO David DeStefano will step down from his roles effective November 10, 2025. Following an extensive search assisted by an ...

Conestoga Capital Advisors, an asset management company, released its third-quarter 2025 investor letter. A copy of the letter can be downloaded here. Equity markets continued their momentum that ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min A former executive at Microsoft ...

News headlines Vertex Pharmaceuticals (VRTX) is gaining traction with strong kidney data and regulatory advancements for its drug povetacicept. The company has raised its revenue guidance for 2025, ...

In another departure from its core focus on genetic medicines, Vertex Pharma has agreed a $4.9 billion purchase of Alpine Immune Sciences, adding a mid-stage drug candidate for kidney disease IgA ...

Men’s Journal aims to feature only the best products and services. If you buy something via one of our links, we may earn a commission. Prices are accurate and items in stock at time of publishing.

Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has been ...

Pfizer is racing towards patent cliffs that will lead to even worse financial results. Vertex Pharmaceuticals is posting strong revenue growth and excellent clinical progress. As a result, Vertex ...

This price reflects trading activity during the overnight session on the Blue Ocean ATS, available 8 PM to 4 AM ET, Sunday through Thursday, when regular markets are closed.

Vertex Minerals (ASX:VTX) has received an exploration licence for the Dun Dun prospect, adjoining the Hill End and Hargraves licences in central west New South Wales. The new licence provides the ...